Release Details
Voyager Therapeutics to Present at the American Society of Gene & Cell Therapy 18th Annual Meeting
Cambridge, Mass., May 5, 2015 – Voyager Therapeutics, a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced that the company will present during multiple sessions at the American Society of Gene & Cell Therapy’s (ASGCT) 2015 Annual Meeting, to be held May 13-16 at the Hyatt Regency in New Orleans, La.
The schedule of Voyager scientific presentations at ASGCT 2015 is as follows:
| Title: | Comparison of CNS Transduction by Different AAV Capsids in Mouse and Non-Human Primate | |
| Date & Time: | Wednesday, May 13, 2015, 5:15-6:45 p.m. | |
Session: | AAV Vectors I | |
| Presenter: | Martin Goulet, Ph.D., senior scientist | |
| Title: | Comparative Analysis In Vitro of Regulatory Elements That Drive Targeted Gene Expression In AAV Vectors | |
| Date & Time: | Wednesday, May 13, 2015, 5:15-6:45 p.m. | |
| Session: | Neurologic Diseases (Including Ophthalmic and Auditory Diseases) I | |
| Presenter: | Pengcheng Zhou, Ph.D., senior scientist | |
| Title: | Optimization of Intrathecal Delivery of AAV for Targeting the Spinal Compartment | |
| Date & Time: | Friday, May 15, 2015, 3:30-5:30 p.m. | |
| Session: | Neurologic Diseases II | |
| Presenter: | Adrian Kells, Ph.D., senior scientist |
In addition, Voyager management will participate in a C-Suite Executive Panel prior to the conference. Presentation details are as follows:
| Title: | Commercialization Workshop, C-Suite Executive Panel | |
| Date & Time: | Tuesday, May 12, 2015, 9:30-10:30 a.m. | |
Session: | Messaging and Other Strategic Tools for Successful Commercialization in a Landscape Where Zero to Few Approved Therapeutics Products Exist | |
| Presenter: | Jeff Goater, senior vice president, finance & business development |
About Voyager Therapeutics
Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing and delivery techniques, as well as process development and production. The company’s pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia and Huntington’s disease. Voyager has broad strategic collaborations with Genzyme, a Sanofi company, and the University of Massachusetts Medical School (UMMS). Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on LinkedIn.
About the American Society of Gene & Cell Therapy (ASGCT)
The American Society of Gene & Cell Therapy (ASGCT) is a professional nonprofit medical and scientific organization dedicated to the understanding, development and application of genetic and cellular therapies and the promotion of professional and public education in the field. For more information on ASGCT, visit its website, www.asgct.org.
###
Voyager Media Contact:
Katie Engleman
Pure Communications, Inc.
910-509-3977